Navigation Links
Rifampin: Latent TB treatment saves time money and lives
Date:5/20/2008

ATS 2008, TORONTOA new way to treat patients with latent tuberculosis (TB), who are infected with TB but without symptoms, can effectively treat it in less than half the time and at a lower cost than the current standard treatment, according to researchers who conducted a multi-center, randomized controlled trial. The results will be presented at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the healthcare system, said lead analyst, Anne Aspler, M.Sc., of the Respiratory Epidemiology & Clinical Research Unit at McGill Universitys Montreal Chest Institute. Overall, Rifampin costs about $484 less per patient treated, which, if we assume that four months of Rifampin has at least equal efficacy to nine months of Isoniazid, represents an added savings to the health system of more than $10,000 per patient prevented from developing TB disease. And because of improvements in compliance, we are actually preventing more cases. This treatment can save money as well as lives.

At present, two billion people are believed to have latent or dormant TB. Of those infected, eight to nine million will develop TB each year, of whom 1.6 million will die. This is one of the most pressing public health crises in our modern world, said Ms. Aspler.

Rifampin is offered in developing countries, where TB presents the greatest burden, at a subsidized cost through the Global Drug Facility of the World Health Organization. In addition to the cost savings, therapy with Rifampin has the advantage of increased compliance.

While Isoniazid therapy is 90 percent effective for those who complete it, in reality, fewer than 50 percent do, Ms. Aspler explained. The high attrition rate can have serious public heath effects, not only for the patients who fail to complete therapy, but also for the individuals they may later infect.

According to previous research and program experience in Maryland and New Jersey, a four-month treatment has been shown to improve compliance by 20 to 25 percent. In addition to better completion rates, a four-month course of Rifampin offers the advantages of fewer adverse reactions (fewer serious side effects such as hepatotoxicity or liver damage), and lower costs.

The next step in research is a major Phase III clinical trial of efficacyideally in HIV-infected and non-infected patients and in low-income settings where tuberculosis is the leading cause of death in people living with HIV, said Ms. Aspler.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. New chemical can kill latent tuberculosis bacteria
2. New treatment gives hope for pulmonary fibrosis patients
3. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
4. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
5. Mapping of prostate cancer genes opens the door to new treatments
6. Many Diabetics Dont Get Necessary Blood Pressure Treatment
7. MR imaging accurately determines prostate cancer treatment failure
8. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
9. Old antibiotic may find new life as a stroke treatment
10. Radiofrequency ablation is effective treatment for dysplasia in Barretts esophagus
11. New Hair Loss Treatment Proves Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 19, 2017 , ... Mr. Noppadon Pakprot, Deputy Governor for ... Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest “Functional & ... Products and Business at TAT said, “Thailand has long been recognized as a ...
(Date:8/18/2017)... New York, New York (PRWEB) , ... ... ... Q International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized ... today announced it has entered into a definitive agreement to purchase Unitrans ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... ... 2017 , ... Hernandez Insurance Agencies, a northern Virginia firm ... DC region, is inaugurating a “New Leash On Life” charity initiative in conjunction ... to be companions for veterans in need. , The Semper K9 organization works ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance Group, ... communities throughout southern Florida, is working to support the Take Stock In Children ... low income families. , The Take Stock In Children Foundation (TSC) offers guidance ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/15/2017)... Aug. 15, 2017  AOTI Inc. announced today that its fully ... has recently opened a New York City Office in ... its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This ... Commission for Health Care (ACHC) under the company,s DMEPOS accreditation for ... ...
Breaking Medicine Technology: